scPharmaceuticals Q2 2025 Earnings Report

scPharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.30
• Beat/Miss: N/A
• One Year Ago EPS: N/A

scPharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $15.41 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

scPharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 13, 2025
• Conference Call Time: 4:30PM ET

scPharmaceuticals (NASDAQ:SCPH) is a clinical-stage biopharmaceutical company focused on developing improved formulations of established oncology therapies through its proprietary SoluMatrix® microcrystal platform. By generating submicron drug particles, the company aims to enhance solubility, reduce infusion times and mitigate adverse reactions commonly associated with high-dose chemotherapy. Its technology is designed to repurpose widely used cytotoxic agents, offering the potential to address unmet needs in cancer treatment without the lengthy timelines required for novel drug discovery.

The company’s lead candidate, SM-101, is a reformulated injectable version of gemcitabine being evaluated in Phase I/II studies for pancreatic and non-muscle invasive bladder cancer. SM-101 has received orphan drug designation from the U.S. Food and Drug Administration for pancreatic cancer, and early clinical results have demonstrated encouraging tolerability and preliminary efficacy signals. In addition to SM-101, scPharmaceuticals is advancing a second oncology program based on a reengineered formulation of paclitaxel, with the goal of reducing infusion-related side effects and broadening patient eligibility for treatment.

Founded in 2009 and headquartered in Bridgewater, New Jersey, scPharmaceuticals conducts its clinical operations across the United States and Europe. The company is led by a management team with extensive experience in oncology development, regulatory affairs and pharmaceutical manufacturing. Under the leadership of CEO Suneel Chilukuri and supported by a board comprising former executives from major pharmaceutical firms, scPharmaceuticals is positioned to leverage its microcrystal technology to potentially improve standard-of-care cancer treatments and deliver value for patients and shareholders alike.